Array Biopharma (ARRY) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Array BioPharma (ARRY) PT Raised to $20 at Leerink Partners
February 7, 2018 7:40 AM ESTLeerink Partners raised its price target on Array BioPharma (NASDAQ: ARRY) to $20.00 (from $19.00) while maintaining a Outperform rating.
... MoreArray BioPharma (ARRY) PT Raised to $19 at Cowen
February 7, 2018 7:05 AM ESTCowen raised its price target on Array BioPharma (NASDAQ: ARRY) to $19.00 (from $17.00) while maintaining a Outperform rating.
Analyst Chris Shibutani commented, "F2Q18 results were highlighted by impressive pipeline updates including COLUMBUS data with greater than expected OS of 33.6 months for COMBO450 in BRAF-mutant... More
Array BioPharma (ARRY) PT Raised to $23 at Stifel
February 7, 2018 6:27 AM ESTStifel raised its price target on Array BioPharma (NASDAQ: ARRY) to $23.00 (from $20.00) while maintaining a Buy rating.
Analyst Stephen Willey commented, "The disclosure of median OS data from the P3 COLUMBUS trial (encorafenib/binimetinib vs. vemurafenib in BRAF-mutant melanoma) provides further confirmation of the pharmacological... More
